PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

BACKGROUND: Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Sylvain, Voillet, Valentin, Vignard, Virginie, Wu, Zhong, Dabrowski, Camille, Jouand, Nicolas, Beauvais, Tiffany, Khammari, Amir, Braudeau, Cécile, Josien, Régis, Adotevi, Olivier, Laheurte, Caroline, Aubin, François, Nardin, Charles, Rulli, Samuel, Gottardo, Raphael, Ramchurren, Nirasha, Cheever, Martin, Fling, Steven P, Church, Candice D, Nghiem, Paul, Dreno, Brigitte, Riddell, Stanley R, Labarriere, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668369/
https://www.ncbi.nlm.nih.gov/pubmed/33188038
http://dx.doi.org/10.1136/jitc-2020-001631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668369/
https://www.ncbi.nlm.nih.gov/pubmed/33188038
http://dx.doi.org/10.1136/jitc-2020-001631

Ejemplares similares